The platinum-chromium stent platform was developed to provide improved deliverability, radiopacity, radial strength, and recoil resistance compared with earlier stainless steel or cobalt-chromium stents.
Design goals may aid platform selection in complex anatomy; leaves open outcome validation versus contemporary stents.
Advances in drug-eluting stent technology have continued to improve clinical outcomes for patients undergoing percutaneous coronary intervention (PCI). The Boston Scientific stent platform has evolved from the 316L stainless steel Express™ stent, to the 316L stainless steel Liberté™ stent, to the cobalt–chromium PROMUS™ stent and, finally, to the platinum–chromium (PtCr) stent series. The PtCr platform, which uses the Element architecture, is designed to have improved deliverability, radiopacity, radial strength and recoil resistance compared with existing stainless steel or cobalt–chromium stents. This review discusses the key points in Boston Scientific’s development programme, which has culminated in the newest generation of coronary stent systems: the PtCr bare-metal OMEGA™ stent, the PtCr paclitaxel-eluting TAXUS Element™ (ION™) stent and the PtCr everolimus-eluting PROMUS Element™ stent systems.
No takes yet. Share an insight, caveat, or question.
Allocco et al. (2011) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: